EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Successful Identification and Treatment of Cancer of Unknown Primary Originating From Gastric Cancer Using Comprehensive Genomic Profiling and Immune Checkpoint Inhibitor Therapy: A Case Report

Takahiro Sasaki iD, Sayaka Yuzawa iD, Hiroki Tanabe iD, Yusuke Ono iD, Keitaro Takahashi iD, Katsuyoshi Ando iD, Nobuhiro Ueno iD, Shin Kashima iD, Kentaro Moriichi iD, Mishie Tanino iD, Yusuke Mizukami iD, Mikihiro Fujiya iD

Cancer Reports · 2025

DOI: 10.1002/cnr2.70338 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cancer Reports, 2025. Verfasst von Takahiro Sasaki und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa, Japan. Hauptthemen laut MEDLINE: Neoplasms, Unknown Primary, Stomach Neoplasms, Immune Checkpoint Inhibitors, Adenocarcinoma. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cancer of unknown primary (CUP) is a challenging malignancy characterized by metastatic tumors with an unidentified primary site, even after extensive pathological and radiographic evaluation. Recent advancements in gene expression profiling and comprehensive genomic profiling (CGP) using next‐generation sequencing (NGS) have enabled the identification of potential tissue origins, thereby facilitating personalized treatment strategies. Although most cases of CUP present as adenocarcinomas or poorly differentiated tumors, the treatment remains largely empirical, with limited success from molecularly tailored therapies. However, advances in tumor DNA sequencing and targeted therapies hold great promise for enhancing patient outcomes. Case A 72‐year‐old woman presented with epigastric pain and was diagnosed with a duodenal tumor and gastric ulceration via esophagogastroduodenoscopy. A histological evaluation revealed poorly differentiated adenocarcinoma in the duodenum, and the immunohistochemistry findings supported a pancreatobiliary origin. An endoscopic ultrasound‐guided biopsy confirmed poorly differentiated adenocarcinoma in the duodenum, while a subsequent gastric examination revealed well‐differentiated adenocarcinoma, suggesting dual malignancies. The patient underwent neoadjuvant chemotherapy, followed by pancreatoduodenectomy with distal gastrectomy. The CUP was staged as poorly differentiated adenocarcinoma (pStage IVB), while the gastric cancer was staged as well‐differentiated adenocarcinoma (pStage IA). Despite adjuvant TS‐1 therapy, lymph node metastasis near the superior mesenteric artery continued to progress. CGP revealed high microsatellite instability and a high tumor mutational burden, along with multiple actionable genetic mutations. Pembrolizumab monotherapy was initiated, leading to complete remission, with no recurrence observed at 1 year after treatment cessation. Genetic and immunohistochemical investigations have identified microsatellite instability in both CUP and gastric cancer tissues, suggesting a shared origin. Targeted gene sequencing confirmed common genetic variations, ultimately revealing that the CUP originated from gastric cancer cells.

Conclusion

This case highlights the critical role of CGP in the diagnosis and treatment of CUP. The use of advanced molecular techniques, including NGS, revealed the gastric origin of CUP and identified actionable biomarkers, leading to successful treatment with immune checkpoint inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasms, Unknown PrimaryStomach NeoplasmsImmune Checkpoint InhibitorsAdenocarcinomaDuodenal NeoplasmsHumansAgedFemaleHigh-Throughput Nucleotide SequencingGastrectomyGene Expression ProfilingPancreaticoduodenectomyNeoadjuvant TherapyBiomarkers, TumorAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

CGPCUPICI

Substanzen

Immune Checkpoint InhibitorsBiomarkers, TumorAntibodies, Monoclonal, Humanizedpembrolizumab

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa, Japan.
  • Department of Diagnostic Pathology, Asahikawa Medical University Hospital, Asahikawa Medical University, Asahikawa, Japan.
  • Oncology Center, Asahikawa Medical University Hospital, Asahikawa, Japan.
  • Institute of Biomedical Research, Sapporo-Higashi Tokushukai Hospital, Sapporo, Japan.

ORCID-Profile: Takahiro Sasaki, Sayaka Yuzawa, Hiroki Tanabe, Yusuke Ono, Keitaro Takahashi, Katsuyoshi Ando, Nobuhiro Ueno, Shin Kashima, Kentaro Moriichi, Mishie Tanino, Yusuke Mizukami, Mikihiro Fujiya

Zitieren

APA

Sasaki, T., Yuzawa, S., Tanabe, H., Ono, Y., Takahashi, K., Ando, K., Ueno, N., Kashima, S., Moriichi, K., Tanino, M., Mizukami, Y., & Fujiya, M. (2025). Successful Identification and Treatment of Cancer of Unknown Primary Originating From Gastric Cancer Using Comprehensive Genomic Profiling and Immune Checkpoint Inhibitor Therapy: A Case Report. Cancer Reports. https://doi.org/10.1002/cnr2.70338

Vancouver

Sasaki T, Yuzawa S, Tanabe H, Ono Y, Takahashi K, Ando K, et al. Successful Identification and Treatment of Cancer of Unknown Primary Originating From Gastric Cancer Using Comprehensive Genomic Profiling and Immune Checkpoint Inhibitor Therapy: A Case Report. Cancer Reports. 2025. doi:10.1002/cnr2.70338

BibTeX
@article{Sasaki2025,
  author = {Sasaki, Takahiro and Yuzawa, Sayaka and Tanabe, Hiroki and Ono, Yusuke and Takahashi, Keitaro and Ando, Katsuyoshi and Ueno, Nobuhiro and Kashima, Shin and Moriichi, Kentaro and Tanino, Mishie and Mizukami, Yusuke and Fujiya, Mikihiro},
  title = {Successful Identification and Treatment of Cancer of Unknown Primary Originating From Gastric Cancer Using Comprehensive Genomic Profiling and Immune Checkpoint Inhibitor Therapy: A Case Report},
  journal = {Cancer Reports},
  year = {2025},
  doi = {10.1002/cnr2.70338}
}
Kostenlos starten →